Stories this month focused on TAVI in low-risk patients, statin safety, the burden of CKM syndrome in the US, and more.

Table 1 reflects recommendations that are substantially revised from the 2020 Hypertrophic Cardiomyopathy Guidelines or were drafted as new recommendations in the 2024 Hypertrophic Cardiomyopathy ...

US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Stage II and III ...

SDPA releases its first Clinical Practice Guidelines on alopecia testing, advancing evidence-based care and strengthening the role of dermatology PAs. We hope these recommendations help streamline ...